Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1398P - The impact of personalized prehabilitation on tolerance to chemotherapy in patients with gastric and oesophageal cancer. A controlled study

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Oesophageal Cancer;  Gastric Cancer

Presenters

Grigorios Christodoulidis

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

G. Christodoulidis1, L.J. Halliday2, V. Wynter-Blyth3, K. Moorthy4, N. Bhuva5

Author affiliations

  • 1 General Surgery, University hospital of Larissa, 41100 - Larissa/GR
  • 2 Surgery And Cancer, Imperial College London, W120HS - London/GB
  • 3 Cancer, Onkohealth, W2 6LG - London/GB
  • 4 Department Of Cancer And Surgery, Imperial College London, W2 1PG - London/GB
  • 5 Clinical Oncology, Mount Vernon Cancer Center, HA62RN - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1398P

Background

Prehabilitation programmes aim to optimise patients preoperatively to enhance post-operative recovery and outcome. Previous studies have demonstrated that prehabilitation can improve pre-operative fitness and can overcome the negative impact of neoadjuvant chemotherapy and chemoradiotherapy on fitness. The aim of this study was to assess the impact of prehabilitation on the tolerance of neoadjuvant chemotherapy in patients with gastric and oesophageal cancer.

Methods

Patients with gastric or oesophageal cancer from two centres were compared; one provided a multimodal prehabilitation programme and one did not offer prehabilitation. The parameters evaluated for comparison between the two groups included age, Karnofsky and ASA scores, tumor location and histology, cycles of chemotherapy and radiotehrapy that were completed.

Results

135 patients were included in this study; 81 patients from the prehabilitation cohort and 54 in the control cohort. Compared with the control group, the prehabilitation group demonstrated improved rate of chemotherapy completion (p=0.002). According to the multivariate analysis, the prehabilitation and radiotherapy were associated with improved tolerance of chemotherapy.

Conclusions

Prehabilitation has previously been shown to negate the negative impact of neoadjuvant chemotherapy on pre-operative fitness. In parallel to this, this study has shown that prehabilitation is also associated with better tolerance of chemotherapy. Further research is needed to establish the long-term impact of prehabilitation on oncological outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Krishna Moorthy.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.